The EpiPen controversy’s bad omens for pharmas

By Joe Mont2016-09-27T12:45:00

At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.

THIS IS MEMBERS-ONLY CONTENT

SINGLE MEMBERSHIP CORPORATE MEMBERSHIP

You are not logged in and do not have access to members-only content.

If you are already a registered user or a member, SIGN IN now.

Article
Mylan nears $30M settlement with SEC in EpiPen investigation

2019-07-31T16:35:00Z By Jaclyn Jaeger

Mylan disclosed in a regulatory filing that it has reached a $30 million agreement-in-principle to resolve the SEC’s investigation alleging securities violations for disclosures surrounding EpiPens.
Blog
Drug company investors set to vote on executive pay, drug prices

2018-04-06T15:45:00Z By Jaclyn Jaeger

A handful of drug makers have lost their battle with investors who had submitted proposals seeking more information on the potential link between executive compensation packages and rising drug prices.
Blog
Mylan will pay $465 million to resolve False Claims Act liability

2017-08-22T12:15:00Z By Joe Mont

Mylan, maker of the EpiPen, has agreed to pay $465 million to settle Department of Justice allegations that it violated the False Claims Act by misclassifying the epinephrine injector as a generic drug to avoid paying Medicaid rebates.

“For tracking litigation, enforcement, and regulatory developments, Compliance Weekshould be your prime source.”

The EpiPen controversy’s bad omens for pharmas

THIS IS MEMBERS-ONLY CONTENT

Related articles

Mylan nears $30M settlement with SEC in EpiPen investigation

Drug company investors set to vote on executive pay, drug prices

Mylan will pay $465 million to resolve False Claims Act liability

“For tracking litigation, enforcement, and regulatory developments, Compliance Week
should be your prime source.”